WARRENDALE, Pa., June 12 /PRNewswire/ -- MEDRAD, INC., has signed a
distribution and co-marketing partnership agreement with PETNET Solutions,
a fully owned subsidiary of Siemens Medical Solutions USA, Inc. The
agreement will enable health care providers to inject Fluorodeoxyglucose
(FDG) for Positron Emission Tomography/Computed Tomography (PET/CT) imaging
procedures in an innovative, new way. The partnership will leverage
MEDRAD's soon to be introduced PET infusion system and multi-dose FDG
packaging and delivery from PETNET Solutions. PET/CT Imaging has proven
effective in diagnosing and staging certain forms of cancer.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040309/MEDRADLOGO )
MEDRAD's PET infusion system, to be called Intego(TM), is designed to
automatically extract a patient dose from a multi-dose vial and deliver it
directly to the patient. The system is mobile and includes dosimetry,
shielding, and a touchscreen interface -- all with precision, flexibility,
and safety in mind.
PETNET Solutions has agreed to provide FDG to customers throughout its
extensive, cyclotron-based radiopharmacy network in multi-dose vials and
specially designed vial shields, which will allow for easy integration with
MEDRAD's new system.
Michael Reitermann, chief executive officer, Molecular Imaging, Siemens
Medical Solutions USA, Inc., commented, "In addition to our traditional
delivery method, by providing FDG in multi-dose vials compatible with the
MEDRAD PET infusion system across our extensive network, we have the
opportunity to help improve the way FDG is being handled and delivered."
Alan Connor, director of global marketing for MEDRAD Molecular Imaging,
said, "We are very pleased that PETNET Solutions is the first FDG provider
to agree to provide FDG in a manner compatible with the Intego System
across its entire network. From the beginning of this project, PETNET
Solutions has been instrumental to the development of this system and is
dedicated to providing the latest in safety and clinical performance to
their customers."
MEDRAD will show the system at the annual Society of Nuclear Medicine
(SNM) meeting in New Orleans, Louisiana, on June 13-16.
About MEDRAD
MEDRAD, INC., is a worldwide leading provider of medical devices and
services that enable and enhance imaging procedures of the human body. Used
in diagnostic imaging, MEDRAD's product offerings include a comprehensive
line of vascular injection systems, magnetic resonance (MR) surface coils
and patient care products, and equipment services. Total 2007 revenues were
$525 million. MEDRAD is a 2003 recipient of the Malcolm Baldrige National
Quality Award, the top honor a U.S. company can receive for quality and
business excellence. The company's world headquarters is near Pittsburgh,
Pennsylvania, in the United States. MEDRAD is an affiliate of Bayer AG.
The Bayer Group is a global enterprise with core competencies in the
fields of healthcare, nutrition and high-tech materials. Bayer HealthCare,
a subsidiary of Bayer AG, is one of the world's leading, innovative
companies in the healthcare and medical products industry and is based in
Leverkusen, Germany. The company combines the global activities of the
Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions.
The pharmaceuticals business operates under the name Bayer Schering Pharma
AG. Bayer HealthCare's aim is to discover and manufacture products that
will improve human and animal health worldwide. Find more information at
http://www.bayerhealthcare.com.
About PETNET Solutions
PETNET Solutions, a fully owned subsidiary of Siemens Medical
solutions, operates the largest PET radiopharmacy network with over 44
radiopharmacies and distribution centers at multiple locations that produce
and distribute PET radiopharmaceuticals to hospitals, clinics, and research
facilities for PET imaging.
Cautionary statement regarding forward-looking statement.
Certain statements in this press release that are neither reported
financial results nor other historical information are forward-looking
statements, including but not limited to, statements that are predictions
of or indicate future events, trends, plans or objectives. Undue reliance
should not be placed on such statements because, by their nature, they are
subject to known and unknown risks and uncertainties and can be affected by
other factors that could cause actual results and MEDRAD's plans and
objectives to differ materially from those expressed or implied in the
forward-looking statements. MEDRAD, INC., undertakes no obligation to
update publicly or revise any of these forward-looking statements, whether
to reflect new information or future events or circumstances or otherwise.
SOURCE MEDRAD, INC.
 back to top
Related links:
http://www.medrad.com
http://www.bayerhealthcare.com
Photo Notes:
NewsCom: http://www.newscom.com/cgi-bin/prnh/20040309/MEDRADLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Alan Connor of MEDRAD Molecular Imaging,
+1-412-767-2400 Ext. 3616, aconnor@medrad.com, or Dan Dieter of
MEDRAD Marketing Services, +1-724-940-6949, ddieter@medrad.com
|
